About Micar Innovation
Micar Innovation is a AI drug discovery engine. Micar Innovation creates new companies in partnership with pioneering academic researchers and major biopharmaceutical companies, which provide funding and a path to liquidity through pre-negotiated acquisitions.
Discovering novel small molecule and the demonstration of true non-clinical proof-of-concept is a key value-creation step in the clinical development of a medicine.
Micar Innovation seeks to develop product candidates that:
Address currently unmet medical needs // Suggest a clear-cut development profile // Provide an opportunity to be first-in-class or best-in-class
Micar Innovation is actively developing promising first-in-class or best-in-class therapies to treat unmet diseases and rare genetic diseases, which mostly affect children. The company has a growing product pipeline, with multiple preclinical candidates in development.
Drug discovery operations are built around an experienced team of researchers. Previous accomplishments of Micar Innovation team members led to preclinical-stage drugs in diverse disease areas including neurology, oncology, rare diseases. Micar Innovation business model includes “Build-to-Buy” partnerships, where world-class academic researchers are matched with pharmaceutical partners to form new drug discovery programs for the Micar Innovation team to execute upon. New start-up companies are spun-out for translation of these programs into novel therapies, incorporating an exclusive option for a pharmaceutical partner to acquire a spun-out company downstream at pre-set terms. Micar Innovation has now formed multiple companies around discovery programs subject to Build-to-Buy agreements.
